CONMED Corp SEC 10-K Report
CONMED Corporation has released its 2025 Form 10-K report, revealing a 5.2% increase in net sales to $1,374.7 million but a significant decrease in net income to $47.1 million due to higher operating expenses and tax rates. The company is focusing on strategic initiatives such as product portfolio optimization, a share repurchase program, and exploring acquisitions, while navigating challenges like regulatory compliance, supply chain disruptions, and competitive market pressures.
A Look At CONMED (CNMD) Valuation After Earnings And Growth In Key Surgical Segments
CONMED (CNMD) shares are gaining attention after reporting strong Q4 and full-year 2025 results, issuing positive 2026 revenue guidance, and showcasing momentum in key surgical segments. Despite a recent dip in its stock price over the last year, the company is trading at a significant discount to its estimated fair value, suggesting a potential undervaluation at US$39.93 against a fair value of US$48.40. Investors are now evaluating whether this indicates a mispriced opportunity or if market concerns about supply chain issues and hospital budget pressures overshadow its long-term growth prospects, particularly in minimally invasive and robotic-assisted surgeries.
5 Must-Read Analyst Questions From CONMED's Q4 Earnings Call
CONMED (CNMD) reported strong Q4 results, exceeding revenue and adjusted EPS estimates, largely driven by its orthopedics portfolio and resolving supply chain issues. The company is strategically shifting focus to high-growth areas like robotic surgery and orthopedics while exiting lower-growth product lines. Analyst questions focused on revenue seasonality, organic growth figures, drivers of orthopedic outperformance, international demand, and future M&A strategy.
Conmed Corporation stock hits 52-week low at 38.05 USD
Conmed Corporation's stock has hit a 52-week low at $38.05, reflecting a significant decline over the past year with a 1-year total return of -44.43%. Despite the stock's underperformance, InvestingPro analysis indicates that the company maintains strong fundamentals, including a current ratio of 2.1, and is projected to be profitable this fiscal year. This comes after the medical technology firm reported stronger-than-expected earnings and revenue for Q4 2025, with an adjusted EPS of $1.43 and revenue of $373.2 million.
CONMED Corporation (NYSE:CNMD) Q4 2025 Earnings Call Transcript
CONMED Corporation (NYSE:CNMD) reported a strong Q4 and full-year 2025, with total sales increasing 7.9% and 5.2% respectively. The company beat earnings expectations with an adjusted EPS of $1.43 against an expected $1.32. CONMED is narrowing its focus to high-growth, high-margin markets, exiting gastroenterology product lines, and making significant progress in its orthopedic supply chain and key growth platforms like AirSeal, Buffalo Filter, and BioBrace, while also announcing a CFO transition.
CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook
CONMED (NYSE:CNMD) reported better-than-expected Q4 CY2025 revenue, up 7.9% year-on-year, driven by strong orthopedics performance and resolved supply chain issues. The company is strategically refocusing on high-growth areas like robotic surgery and exiting lower-growth gastroenterology products, which is projected to improve long-term gross margins despite anticipated headwinds from tariffs. Management's outlook for 2026 reflects confidence in core growth drivers and increased R&D investment, while also acknowledging potential impacts from tariffs and portfolio adjustments on EPS.
CONMED Corp shares slip after Q4 earnings beat, cautious guidance
CONMED Corp (NYSE: CNMD) shares dipped after reporting Q4 2025 earnings that beat expectations but were accompanied by cautious guidance for 2026. Despite moderate growth in Q4 sales and full-year revenue, and an increase in adjusted diluted EPS, the company's stock fell due to the conservative outlook and plans to exit its gastroenterology portfolio to focus on core markets. This has contributed to a recent downtrend and significant volatility in its share price.
Conmed: Fourth Quarter Financial Highlights
Conmed Corp. reported strong financial results for its fourth quarter, with a net profit of $16.7 million and adjusted earnings of $1.43 per share, surpassing analyst expectations. The medical technology firm generated $373.2 million in revenue and provided optimistic annual earnings and revenue projections for the coming year.
(CNMD) CONMED Expects 2026 Revenue Range $1.35B-$1.38B, vs. FactSet Est of $1.38B
CONMED Corporation (CNMD) has provided its preliminary outlook for fiscal year 2026, anticipating total reported revenue to be in the range of $1.35 billion to $1.38 billion. This forecast is slightly below the FactSet estimate of $1.38 billion. The announcement was made following the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference.
CONMED (NYSE:CNMD) Beats Q4 CY2025 Sales Expectations, Stock Soars
CONMED (NYSE:CNMD) reported Q4 CY2025 results that exceeded revenue expectations, with sales up 7.9% year-on-year to $373.2 million and non-GAAP EPS of $1.43, beating analyst estimates by 8%. However, the company's full-year revenue guidance for 2026 slightly missed analysts' estimates, and its operating margin decreased by 5.4 percentage points year-on-year in Q4. Despite mixed results, the stock traded up 5.4% immediately following the announcement, indicating a positive market reception to the revenue beat.
Conmed: Q4 Earnings Snapshot
Conmed Corp. (CNMD) reported strong fourth-quarter earnings, beating Wall Street expectations with $1.43 per share adjusted, compared to an average estimate of $1.32 per share. The medical technology company posted $373.2 million in revenue for the quarter. For the full year, Conmed reported a profit of $47.1 million, or $1.51 per share, on revenue of $1.37 billion, and provided optimistic guidance for the upcoming year.
Earnings Flash (CNMD) CONMED Corporation Reports Q4 Revenue $373.2M, vs. FactSet Est of $366.9M
CONMED Corporation (CNMD) reported its Q4 revenue of $373.2 million, surpassing FactSet's estimate of $366.9 million. The company, a medical technology firm, specializes in surgical devices and equipment for minimally invasive procedures across various medical specialties. This announcement comes amid other recent news including CFO transition and reaffirmation of consolidated earnings guidance for the full year 2025.
(CNMD) CONMED Expects 2026 Adjusted Earnings Range $4.30-$4.45, vs. FactSet Est of $4.50
CONMED (CNMD) has announced its adjusted earnings expectations for 2026, forecasting a range of $4.30 to $4.45 per share. This projection falls below the FactSet estimate of $4.50 per share. The medical technology company's guidance was released on January 28, 2026, alongside its Q4 2025 earnings report.
Conmed: Fourth Quarter Financial Highlights
Conmed Corp. reported strong financial results for the fourth quarter, with a net profit of $16.7 million and adjusted earnings of $1.43 per share, surpassing analyst expectations. The medical technology firm generated $373.2 million in revenue and provided optimistic annual earnings and revenue projections for the future.
CONMED Corporation (CNMD): Stock Analysis Reveals 18% Potential Upside Amidst Healthcare Sector Dynamics
CONMED Corporation (CNMD), a medical device company, is highlighted for its specialized focus on surgical equipment, despite current valuation challenges. The stock holds an 18% potential upside according to analysts, driven by its robust free cash flow, strategic product portfolio, and solid dividend yield. Technical indicators suggest the stock is nearing oversold territory, making it a potential buying opportunity for investors in the medical technology space.
Conmed: Q4 Earnings Snapshot
Conmed Corp. (CNMD) reported strong fourth-quarter earnings, surpassing Wall Street expectations with adjusted earnings of $1.43 per share on revenue of $373.2 million. For the full year, the company posted a profit of $47.1 million and revenue of $1.37 billion. Conmed also provided optimistic full-year guidance, projecting earnings between $4.30 and $4.45 per share and revenue in the range of $1.35 billion to $1.38 billion.
CONMED Earnings: What To Look For From CNMD
CONMED (NYSE:CNMD) is set to announce its earnings results this Wednesday. Analysts expect revenue to grow 6.1% year-on-year to $367 million with adjusted earnings of $1.32 per share. The company has a history of missing Wall Street's revenue estimates and is currently trading below the average analyst price target.
Mountain Pacific Investment Advisers LLC Sells 112,031 Shares of CONMED Corporation $CNMD
Mountain Pacific Investment Advisers LLC significantly reduced its stake in CONMED Corporation (NYSE:CNMD) by selling 112,031 shares, cutting its holdings by 80.1%. This move aligns with a broader negative sentiment from Wall Street analysts, who have issued "Reduce" ratings and lowered price targets for CONMED. Despite this, CONMED slightly surpassed its Q3 EPS estimates and provided positive FY2025 earnings guidance.
Conmed's chief information officer sells $16,796 in common stock
Conmed's Chief Information Officer recently sold 188 shares of the company's common stock, totaling approximately $16,796. This transaction occurred at a price of $89.34 per share. Following this sale, the officer still directly owns 7,994 shares of Conmed stock.
Surgical Equipment & Consumables - Diversified Stocks Q3 Results: Benchmarking CONMED (NYSE:CNMD)
This article analyzes the Q3 earnings results for the surgical equipment and consumables - diversified industry, focusing on CONMED (NYSE:CNMD) and its peers. It highlights CONMED's satisfactory quarter with revenues up 6.7% year-on-year, while also benchmarking it against best performer STERIS (NYSE:STE) and weakest performer BD (NYSE:BDX), along with Solventum (NYSE:SOLV) and Zimmer Biomet (NYSE:ZBH). The industry faces tailwinds from aging populations and integrating AI/robotics, but also headwinds like supply chain issues and regulatory changes.
SG Americas Securities LLC Acquires 61,860 Shares of CONMED Corporation $CNMD
SG Americas Securities LLC significantly increased its stake in CONMED Corporation (NYSE:CNMD) by 3,041.3%, acquiring 61,860 additional shares to hold a total of 63,894 shares valued at approximately $3.01 million. This comes amidst a negative shift in analyst sentiment, leading to multiple price target cuts and a "Reduce" consensus rating for CONMED. Despite this, CONMED recently surpassed quarterly EPS expectations and provided FY2025 guidance.
3 Reasons to Sell CNMD and 1 Stock to Buy Instead
The article analyzes why investors should be cautious with CONMED (CNMD) stock, despite a recent price fall. It highlights three main reasons: lackluster revenue growth, limited distribution channels due to small company size in a scale-driven industry, and slim projected revenue growth. The authors suggest that while the stock appears optically cheap, its shaky fundamentals make it a risky investment, recommending other opportunities instead.
CONMED (NYSE:CNMD) Issues FY 2026 Earnings Guidance
CONMED (NYSE:CNMD) has issued its FY 2026 earnings guidance, projecting EPS between $4.25 and $4.45 and revenue between $1.3 billion and $1.4 billion. These figures are slightly below Street consensus estimates and represent a step down from the company's FY 2025 guidance. Following the announcement, CONMED's shares traded down approximately 0.6%, and analysts have reiterated a "Reduce" rating with an average price target of $53.67.
Conmed Corp - Prelim Outlook FY 2026 Total Reported Revenue $1,345 Million To $1,375 Million - Presentation
Conmed Corp (CNMD) has provided a preliminary outlook for fiscal year 2026, projecting total reported revenue to be between $1,345 million and $1,375 million. This financial forecast was shared in a presentation. The news item is a headline-only release from Reuters.
3 Reasons to Avoid CNMD and 1 Stock to Buy Instead
This article recommends avoiding CONMED (CNMD) due to its lackluster revenue growth, limited distribution channels compared to larger competitors, and slim projected revenue growth. Despite a recent 20.6% stock drop and a reasonable forward P/E, the company's fundamentals are seen as too risky. The authors suggest a dominant Aerospace business as a better investment alternative.
CONMED CFO Todd Garner to step down in March 2026
CONMED Corporation announced that its CFO, Todd Garner, will step down on March 15, 2026, after eight years in the role, but will remain as an advisor through November 2, 2026, for a smooth transition. The company has begun searching for his successor and confirmed his departure is not due to financial statement disagreements. CONMED also reaffirmed its full-year 2025 financial guidance and is optimizing its portfolio by exiting gastroenterology product lines.
CONMED changes its finance chief but keeps 2025 goals on track
CONMED Corporation announced that its Chief Financial Officer, Todd Garner, will step down on March 15, 2026, but will remain in an advisory role through November 2, 2026, to ensure a smooth transition. The company has initiated a comprehensive search for his successor. CONMED reaffirmed its full-year 2025 consolidated revenue and adjusted EPS guidance, emphasizing that Garner's departure is not due to any financial disagreements.
CONMED Announces Planned CFO Transition and Successor Search
CONMED Corporation announced that CFO Todd Garner will transition out of his role by March 15, 2026, or earlier if a successor is named, though he will remain as a consultant until November 2, 2026. The company is initiating an external search for a new CFO, emphasizing that Garner's departure is not due to disagreements over operations or financial practices. CNMD currently holds a "Hold" rating from analysts with a $44.00 price target.
CONMED Corporation Announces Chief Financial Officer Transition
CONMED Corporation announced that Todd Garner will step down as CFO on March 15, 2026, and will remain in an advisory role until November 2, 2026. The company has initiated a search for a new CFO and reaffirmed its full-year 2025 revenue and adjusted EPS guidance. His departure is not due to any disagreement regarding the company's financial statements.
CONMED Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
CONMED Corporation announced that its President and CEO, Patrick J. Beyer, and Executive Vice President and CFO, Todd W. Garner, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. A live audio webcast of the presentation will be available on the company's website. CONMED is a medical technology company specializing in surgical devices and equipment across various medical specialties.
CONMED Corporation to Announce Fourth Quarter 2025 Financial Results on January 28, 2026
CONMED Corporation (NYSE: CNMD) announced it will report its financial results for the fourth quarter of 2025 after market close on Wednesday, January 28, 2026. The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results. The call will also be webcast and accessible from the Investors section of CONMED's website.
Is There An Opportunity In CONMED (CNMD) After A 38% One Year Share Price Fall
CONMED (CNMD) has seen a significant 38.2% drop in its share price over the past year. Despite this, a Discounted Cash Flow (DCF) analysis by Simply Wall St suggests the stock is currently undervalued by 42.2%, with an intrinsic value of US$72.45 per share compared to its recent trading price of US$41.88. The company's P/E ratio of 20.24x also sits below both the industry average and Simply Wall St's proprietary "Fair Ratio," indicating it may be trading at a discount.
CONMED leaders to share company update at J.P. Morgan Healthcare Conference
CONMED Corporation announced that its President and CEO, Patrick J. Beyer, and EVP and CFO, Todd W. Garner, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 12, 2026, at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco, CA, and will be webcast live on the company's website. CONMED is a medical technology company specializing in devices and equipment for surgical procedures across various specialties.
What CONMED’s Jan. 28 earnings call could reveal about 2025
CONMED Corporation announced it will release its fourth-quarter 2025 financial results after the market close on Wednesday, January 28, 2026. The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results. Interested parties can pre-register for the call or access the webcast through CONMED's investor relations website.
CONMED (NYSE:CNMD) Rating Lowered to Strong Sell at Zacks Research
Zacks Research has downgraded CONMED (NYSE:CNMD) from a "hold" to a "strong sell" rating, reflecting increased negative sentiment. This follows several other analysts lowering price targets, resulting in a "Reduce" consensus rating and an average target price significantly above the current trading price. Despite the negative analyst sentiment, CONMED recently surpassed quarterly EPS and revenue estimates and provided positive FY2025 guidance.
Will Exiting Gastroenterology to Refocus on Core Surgery Change CONMED’s (CNMD) Margin Expansion Narrative?
CONMED (NYSE:CNMD) is exiting its gastroenterology business to focus on minimally invasive, robotic, and orthopedic soft tissue surgery. This strategic shift aims to improve margins and align with core surgical growth, though it removes a revenue contributor and introduces execution risks as the company navigates supply chain issues and profitability challenges. CONMED projects $1.6 billion revenue and $154.0 million earnings by 2028, with a fair value estimate of $54.00 per share, representing a 36% upside.
Why CONMED (CNMD) Stock Is Trading Up Today
Shares of medical tech company CONMED (CNMD) rose 3.3% following the highly successful IPO of medical supply giant Medline (MDLN), which boosted investor confidence in the medical device sector. Additionally, CMR Surgical received FDA clearance for its robotic surgical system, further signaling innovation in the medical technology space. Despite this positive movement, CONMED's shares are still down 40.5% year-to-date and have experienced volatility, recently dropping due to a strategic exit from gastroenterology product lines.
Why CONMED (CNMD) Stock Is Trading Up Today
Shares of medical tech company CONMED (NYSE:CNMD) saw a 3.3% jump due to positive sentiment in the medical device sector spurred by Medline's successful IPO and FDA clearance for CMR Surgical's robotic system. Despite this, CONMED's shares remain volatile, having dropped previously after announcing its exit from certain gastroenterology product lines. The stock is down 40.5% year-to-date and 45.9% below its 52-week high, indicating a challenging year for investors.
CONMED (CNMD) Valuation Review as It Exits Gastroenterology and Refocuses on Core Growth Areas
CONMED (CNMD) is exiting gastroenterology, accelerating the end of its GORE VIABIL biliary stent distribution deal as Olympus takes over U.S. rights in early 2026. Despite a significant recent stock decline, the company is considered 27.4% undervalued, with a fair value of $54 according to a narrative driven by the adoption of minimally invasive surgeries and strong product positioning. However, challenges like supply chain issues and hospital spending could impact its recovery.
CONMED Stock Falls as It Strategically Exits Gastroenterology Portfolio
CONMED Corporation (CNMD) announced its strategic exit from the gastroenterology product lines, including an early termination of its agreement with W. L. Gore & Associates for the VIABIL biliary stent. This move aims to sharpen the company's focus on its core growth areas: minimally invasive and orthopedic soft tissue surgery, to enhance its long-term margin profile. Following the announcement, CONMED's shares plunged over 9%, though the company reaffirmed its 2025 revenue and adjusted EPS guidance, anticipating improved consolidated gross margins by about 80 basis points post-exit.
B of A Securities Maintains CONMED (CNMD) Neutral Recommendation
B of A Securities has maintained a Neutral recommendation for CONMED (CNMD), with an average one-year price target of $55.08, suggesting a 37.46% upside. The company is projected to see a 1.60% increase in annual revenue and a non-GAAP EPS of 4.71. Institutional ownership remains significant, with several funds holding substantial stakes.
Conmed to exit gastroenterology business, ends Gore distribution deal
CONMED Corporation (NYSE:CNMD) announced its strategic decision to exit its gastroenterology product lines and terminate its distribution agreement with W. L. Gore & Associates for the VIABIL biliary stent, effective January 1, 2026. This move aims to allow CONMED to focus resources on its core markets in minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. Despite an anticipated EPS dilution of $0.45-$0.55 in 2026, the company expects an 80 basis point improvement in its consolidated gross margin profile and reaffirmed its 2025 financial guidance.
Conmed stock hits 52-week low at 40.0 USD
Conmed Corporation's stock has fallen to a 52-week low of 40.0 USD, representing a 43.23% decline over the past year despite a "GREAT" financial health rating and recent positive earnings, according to InvestingPro data. The medical technology company is streamlining its portfolio by exiting gastroenterology product lines and ending a distribution agreement to focus on core markets, a strategic move being closely watched by stakeholders.
Why Is Conmed Stock Falling Friday? - Conmed (NYSE:CNMD)
Conmed Corporation's stock fell on Friday after the company announced it would exit its gastroenterology product lines to sharpen its focus on higher-growth surgical markets. While this move is expected to cause near-term EPS dilution, CONMED anticipates improved profitability and a stronger consolidated gross margin profile in the long run. The company reaffirmed its 2025 revenue and adjusted earnings guidance.
CONMED (NYSE: CNMD) to leave gastroenterology, speed Gore VIABIL exit and flag 2026 EPS dilution
CONMED Corporation announced its strategic decision to exit its gastroenterology product lines and accelerate the conclusion of its distribution agreement with Gore for VIABIL biliary stents to January 1, 2026. This move aligns with CONMED's focus on minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair. The company expects $90 million to $95 million in gastroenterology revenue for 2025, projects an EPS dilution of $0.45-$0.55 in 2026, but reaffirms its 2025 revenue and adjusted EPS guidance.
CONMED to Exit Gastroenterology Market
CONMED Corp. announced its intent to exit its gastroenterology product lines to optimize its portfolio and focus on core markets like minimally invasive surgery and orthopedic soft tissue repair. This strategic move aims to align operations and resources more effectively, despite the gastroenterology products being anticipated to garner $90 million in revenue this year. The company expects an EPS dilution of $0.45–$0.55 next year due to this exit but reaffirmed its prior financial guidance for 2025.
Conmed to exit gastroenterology product lines, transfer Gore Viabil rights to Olympus
Conmed announced its strategic decision to exit gastroenterology product lines, including its distribution agreement for the Gore Viabil biliary endoprosthesis, to focus on core markets like minimally invasive surgery. This move, which Conmed expects to cause EPS dilution in 2026 but improve consolidated gross margin, transfers Viabil distribution rights to Olympus starting January 1, 2026. Olympus will assume commercial support for the Viabil stent, ensuring continued patient and physician access.
CONMED Corp Announces Strategic Exit from Gastroenterology Product Lines
CONMED Corp has announced its strategic exit from its gastroenterology product lines, including ending the distribution of Gore® VIABIL® stent by January 1, 2026. This move is part of a portfolio optimization strategy aimed at focusing on core markets and is expected to improve gross margin by 80 basis points post-exit, despite an anticipated EPS dilution of $0.45–$0.55 in 2026. The company reaffirmed its 2025 revenue and EPS guidance, expecting no material impact from this decision.
CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines
CONMED Corporation announced its strategic exit from all gastroenterology product lines to concentrate on core markets like minimally invasive surgery and orthopedic soft tissue repair. This move includes accelerating the termination of its distribution agreement with Gore for the VIABIL® biliary stent, effective January 1, 2026. While the exit is expected to result in EPS dilution of $0.45-$0.55 in 2026, it is projected to improve CONMED’s consolidated gross margin profile by approximately 80 basis points and the company reaffirmed its 2025 revenue and EPS guidance.
Why CONMED (CNMD) Shares Are Plunging Today
Shares of medical tech company CONMED (NYSE:CNMD) fell 6.2% after the company announced its plan to exit its gastroenterology product lines as part of a broader portfolio adjustment. Despite the company reaffirming its financial guidance and projecting improved gross margins, investors focused on the loss of a significant revenue stream. This move resulted in a significant stock decline, with CONMED now down 38.3% year-to-date.
